SynthesisBMC endocrine disorders2026
Effects of androgen therapy on final adult height in boys with constitutional delay of growth and puberty: a meta-analysis of retrospective cohort studies.
Synthesis in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the effect of short-term androgen therapy on final adult height in boys with constitutional delay of growth and puberty (CDGP).
methodsOriginal studies investigating androgen therapy in children with CDGP and reporting final adult height as an outcome were retrieved from PubMed, Embase, Web of Science, and SpringerLink. The search period extended from database inception to September 2025. EndNote 20.0 was used for duplicate removal, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). Literature screening, data extraction, and quality assessment were independently conducted by two researchers, with discrepancies resolved through consultation with a third researcher. Meta-analysis was performed using R 4.5.2 and Review Manager 5.4.1.
resultsA total of 13 eligible retrospective cohort studies involving 803 patients were included. Sensitivity analyses demonstrated good robustness of the pooled results, and Egger's tests indicated no significant publication bias (P
conclusionShort-term androgen therapy can improve final adult height in boys with CDGP, with low-dose, short-course testosterone regimens appearing to be the most favorable option. Given the limited number and retrospective nature of the included studies, these findings require further confirmation through high-quality comparative studies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.